GENE ONLINE|News &
Opinion
Blog

2021-11-08| In-DepthSpecial

New Research Marks a Paradigm Shift in Countering Alzheimer’s Disease

by Arvind C. Shekhar
Share To
Alzheimer's disease (AD) is the most common neurodegenerative disease, with more than 40 million cases reported worldwide. AD is characterized by the aggregation of both the β-Amyloid (Aβ) proteins into plaques and of the tau proteins into neurofibrillary tangles (NFTs) known collectively as aggregates which cause brain cells to die and the brain to shrink.

It had been believed that aggregation begins in a single location, spreading from one brain region to the next. A key limiting factor in disease progression is at what rate these processes occur and how important the local replication of seeds and their spread over longer length scales between brain regions, are for determining the time scale of human disease. 

Recent results, reported in the journal Science Advances, have opened up new avenues of understanding the progress of Alzheimer's and other neurodegenerative diseases and possibly new ways that future treatments might be developed.

The researchers developed a mathematical model to simulate the progression of the disease and applied it to five different imaging datasets. By combining the five different datasets, the researchers observed that the mechanism controlling the rate of progression in Alzheimer's disease is the replication of aggregates in individual regions of the brain and not the spread of aggregates from one region to another.

GO Prime with only $1.49 now

LATEST
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment
2024-09-04
Alnylam Pharma Shares Dip Despite Positive Phase 3 HELIOS-B Heart Disease Results
2024-09-04
EVENT
2024-09-11
2024 Bio Asia Pacific
Bangkok, Thailand
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top